Researchers see potential of oral MS pill

06/23/2008 | Yahoo!

Multiple sclerosis patients who received oral doses of laquinimod, an immune-modulating drug, showed a 40% reduction in the cumulative number of active brain lesions seen on MRI scans over 36 weeks when compared with those who got a placebo, a multinational team of researchers reported. Two Mayo Clinic experts, however, underscored the need for more safety studies of the treatment.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care